NEW DELHI: Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60 in India in May from April in its second full month of being on offer in the South Asian country, which has the world’s third-highest number of obese people.
The US drugmaker sold 126 million rupees (US$1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its five milligram version more than doubled to about 75 million rupees, while revenue from the 2.5 mg shot was 51 million rupees.
